Literature DB >> 6240930

Comparative effects of long term treatment with etodolac, naproxen and ibuprofen on articular and bone changes associated with adjuvant arthritis in rats.

R R Martel, J Klicius, G Metcalf, G A Rona.   

Abstract

The effect of prolonged treatment with etodolac (8 mg/kg) on the articular and bone pathology at the tibiotarsal joint associated with adjuvant arthritis in the rat has been studied and compared to the effects produced by treatment with naproxen (8 mg/kg) and ibuprofen (50 mg/kg). Drug effects were assessed by radiologic and histopathologic examinations. The effects on hindpaw edema, hindleg function, and body weight gain were also evaluated. Treatment was initiated on day 16 after adjuvant injection and continued for 28, 56 or 84 days. The degree of relapse which occurred after a 28 day period without treatment following 28 or 56 days of treatment was also assessed. Etodolac prevented the progression of the disease. Further, it appeared to diminish the incidence and severity of the lesions already present on day 16 before drug treatment began. All the parameters measured were improved and there was good agreement between the radiologic and histopathologic assessments of joint damage. At the doses used, the onset of drug activity was more rapid with etodolac than with either of the other two drugs. By comparison naproxen and ibuprofen inhibited the progression of joint damage, but neither drug consistently decreased the magnitude of the joint damage below that of day 16. With all three drugs there was less resurgence of disease symptoms when treatment was stopped after 56 days rather than 28 days of drug administration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6240930     DOI: 10.1007/bf01972379

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  9 in total

1.  A simple precise method for measuring rodent paw volume.

Authors:  J M Hall; C Hallett
Journal:  J Pharm Pharmacol       Date:  1975-08       Impact factor: 3.765

2.  An X-ray analysis of adjuvant arthritis in the rat. The effect of prednisolone and indomethacin.

Authors:  A Blackham; J W Burns; J B Farmer; H Radziwonik; J Westwick
Journal:  Agents Actions       Date:  1977-03

3.  Anti-inflammatory and analgesic properties of etodolic acid in rats.

Authors:  R R Martel; J Klicius
Journal:  Can J Physiol Pharmacol       Date:  1976-06       Impact factor: 2.273

4.  Effect of etodolac on articular and bone pathology associated with adjuvant arthritis in rats: a comparison with aspirin and naproxen.

Authors:  R R Martel; J Klicius; G Metcalf
Journal:  Agents Actions       Date:  1984-02

5.  Comparative efficacy of etodolac and placebo in rheumatoid arthritic patients.

Authors:  G Vetter; M Placchi; L Joubert
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-05

6.  Comparison in rats of the anti-inflammatory and gastric irritant effects of etodolac with several clinically effective anti-inflammatory drugs.

Authors:  R R Martel; J Klicius
Journal:  Agents Actions       Date:  1982-07

7.  Effects of naproxen on connective tissue changes in the adjuvant arthritic rat.

Authors:  N R Ackerman; W H Rooks; L Shott; H Genant; P Maloney; E West
Journal:  Arthritis Rheum       Date:  1979-12

8.  Comparative effects of benoxaprofen and other anti-inflammatory drugs on bone damage in the adjuvant arthritic rat.

Authors:  D N Benslay; R Nickander
Journal:  Agents Actions       Date:  1982-07

9.  An analysis of piroxicam in rodent models of arthritis.

Authors:  I G Otterness; D L Larson; J G Lombardino
Journal:  Agents Actions       Date:  1982-07
  9 in total
  9 in total

1.  Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat.

Authors:  G Engelhardt; D Homma; C Schnitzler
Journal:  Inflamm Res       Date:  1995-12       Impact factor: 4.575

Review 2.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 3.  Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.

Authors:  J A Balfour; M M Buckley
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

4.  Effect of etodolac on type-II collagen-induced arthritis in mice.

Authors:  K Inoue; A Motonaga; H Suzuka; H Yoshifusa; H Fujisawa; T Nishimura; Y Inoue; F Ueda; Y Shibata; K Kimura
Journal:  Agents Actions       Date:  1993-07

5.  Inhibition of prostaglandin biosynthesis by etodolac. I. Selective activities in arthritis.

Authors:  R G Neuman; B D Wilson; M Barkley; E S Kimball; B M Weichman; D D Wood
Journal:  Agents Actions       Date:  1987-06

6.  International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy.

Authors:  D Briancon
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

Review 7.  Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use.

Authors:  S Lynch; R N Brogden
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

8.  Naproxen treatment inhibits articular cartilage loss in a rat model of osteoarthritis.

Authors:  David N Paglia; Deboleena Kanjilal; Yazan Kadkoy; Spiro Moskonas; Charlene Wetterstrand; Anthony Lin; Joseph Galloway; Jeffrey Tompson; Maya D Culbertson; J Patrick O'Connor
Journal:  J Orthop Res       Date:  2020-12-15       Impact factor: 3.102

9.  Combining naproxen and a dual amylin and calcitonin receptor agonist improves pain and structural outcomes in the collagen-induced arthritis rat model.

Authors:  Anna Katri; Aneta Dąbrowska; Henrik Löfvall; Ming Ding; Morten A Karsdal; Kim V Andreassen; Christian S Thudium; Kim Henriksen
Journal:  Arthritis Res Ther       Date:  2019-02-22       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.